Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

Cited In for PubMed (Select 18155364)

1.

The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales.

Marteau D, McDonald R, Patel K.

BMJ Open. 2015 May 29;5(5):e007629. doi: 10.1136/bmjopen-2015-007629.

2.

Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.

Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B.

Addiction. 2015 Jun;110(6):996-1005. doi: 10.1111/add.12863. Epub 2015 Mar 15.

3.

Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.

Bentzley BS, Barth KS, Back SE, Book SW.

J Subst Abuse Treat. 2015 May;52:48-57. doi: 10.1016/j.jsat.2014.12.011. Epub 2014 Dec 30.

PMID:
25601365
4.

Central registry in psychiatry: A structured review.

Prakash J, Ramakrishnan Ts, Das RC, Srivastava K, Mehta S, Shashikumar R.

Ind Psychiatry J. 2014 Jan;23(1):10-4. doi: 10.4103/0972-6748.144939. Review.

5.

Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.

Schuman-Olivier Z, Claire Greene M, Bergman BG, Kelly JF.

Drug Alcohol Depend. 2014 Nov 1;144:178-85. doi: 10.1016/j.drugalcdep.2014.09.009. Epub 2014 Sep 18.

PMID:
25267606
6.

Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance.

Jaremko KM, Sterling RC, Van Bockstaele EJ.

J Subst Abuse Treat. 2015 Jan;48(1):117-27. doi: 10.1016/j.jsat.2014.08.006. Epub 2014 Aug 29.

PMID:
25239858
7.

Methadone toxicity in a poisoning referral center.

Taheri F, Yaraghi A, Sabzghabaee AM, Moudi M, Eizadi-Mood N, Gheshlaghi F, Farajzadegan Z.

J Res Pharm Pract. 2013 Jul;2(3):130-4. doi: 10.4103/2279-042X.122387.

8.

The necessity of checking the status and performance of methadone maintenance treatment centers in iran.

Mohebi MD.

Int J High Risk Behav Addict. 2013 Winter;1(4):139-40. doi: 10.5812/ijhrba.10446. Epub 2013 Mar 12. No abstract available.

9.

Emerging adult age status predicts poor buprenorphine treatment retention.

Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ.

J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. Epub 2014 May 20.

PMID:
24953168
10.

Accounting for individual differences and timing of events: estimating the effect of treatment on criminal convictions in heroin users.

Røislien J, Clausen T, Gran JM, Bukten A.

BMC Med Res Methodol. 2014 May 17;14:68. doi: 10.1186/1471-2288-14-68.

11.

Mortality among methadone maintenance clients in China: a six-year cohort study.

Cao X, Wu Z, Li L, Pang L, Rou K, Wang C, Luo W, Yin W, Li J, McGoogan JM; National Methadone Maintenance Treatment Program Working Group.

PLoS One. 2013 Dec 12;8(12):e82476. doi: 10.1371/journal.pone.0082476. eCollection 2013.

12.

Methadone treatment providers' views of drug court policy and practice: a case study of New York State.

Csete J, Catania H.

Harm Reduct J. 2013 Dec 5;10:35. doi: 10.1186/1477-7517-10-35.

13.

Interim versus standard methadone treatment: a benefit-cost analysis.

Schwartz RP, Alexandre PK, Kelly SM, O'Grady KE, Gryczynski J, Jaffe JH.

J Subst Abuse Treat. 2014 Mar;46(3):306-14. doi: 10.1016/j.jsat.2013.10.003. Epub 2013 Oct 14.

14.

A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study.

Bukten A, Røislien J, Skurtveit S, Waal H, Gossop M, Clausen T.

BMC Psychiatry. 2013 Oct 16;13:262. doi: 10.1186/1471-244X-13-262.

15.

Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ.

Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. Epub 2013 May 18.

16.

Retention in methadone and buprenorphine treatment among African Americans.

Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O'Grady KE, Olsen YK, Schwartz RP.

J Subst Abuse Treat. 2013 Sep;45(3):287-92. doi: 10.1016/j.jsat.2013.02.008. Epub 2013 Apr 5.

17.

Mortality among people who inject drugs: a systematic review and meta-analysis.

Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M.

Bull World Health Organ. 2013 Feb 1;91(2):102-23. doi: 10.2471/BLT.12.108282. Review.

18.

Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH.

Am J Public Health. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14.

19.

Diversity in causes and characteristics of drug-induced deaths in an urban setting.

Gjersing L, Jonassen KV, Biong S, Ravndal E, Waal H, Bramness JG, Clausen T.

Scand J Public Health. 2013 Mar;41(2):119-25. doi: 10.1177/1403494812472007. Epub 2013 Jan 9.

20.

Pharmacological maintenance treatments of opiate addiction.

Bell J.

Br J Clin Pharmacol. 2014 Feb;77(2):253-63. doi: 10.1111/bcp.12051. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk